Traws Pharma Inc. has announced the initiation of Phase 2 clinical studies for Ratutrelvir (TRX01), a novel oral antiviral developed for newly diagnosed COVID-19 patients. Ratutrelvir is designed as a ritonavir-free treatment and aims to address the needs of populations who are ineligible for current standard-of-care antiviral options, such as PAXLOVID®. The drug has shown broad-spectrum in vitro activity against multiple SARS-CoV-2 strains and maintains high potency without the need for ritonavir co-administration, potentially reducing drug-drug interactions. In Phase 1 multiple ascending dose studies, the daily oral regimen demonstrated sustained plasma concentrations above key efficacy thresholds for a 10-day course and was reported to have an excellent safety profile. The results of the Phase 2 clinical study have not yet been presented and will be announced in the future.